Lowell L. Hart, Hope S. Rugo, VK Gadi, Priyanka Sharma, Sarah L. Sammons, Panagiotis Mavros, Maneet Kaur, Nada Boualam, Catherine Keane, Gary Mark Sopher, Purnima Pathak, Paolo Tarantino. "(RW) post-progression outcomes after first-line (1L) treatment with ribociclib + an aromatase inhibitor (AI) vs AI alone in US patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.e13044